참고문헌
- Anderson, G. D. (1998) A mechanistic approach to antiepileptic drug interactions. Ann. Pharmacother. 32, 554-563. https://doi.org/10.1345/aph.17332
- Carter, B. L., Garnett, W. R., Pellock, J. M., Stratton, M. A. and Howell, J. R. (1981) Effect of antacids on phenytoin bioavailability. Ther. Drug Monit. 3, 333-340. https://doi.org/10.1097/00007691-198104000-00003
- Frigo, G. M., Lecchini, S., Caravaggi, M., Gatti, G., Tonini, M., D'Angelo, L., Perucca, E. and Crema, A. (1983) Reduction of phenytoin clearance caused by cimetidine. Eur. J. Clin. Pharmacol. 25 , 135-137. https://doi.org/10.1007/BF00544030
- Goldstein, J. A., Ishizaki, T., Chiba, K., de Morais, S. M., Bell, D., Krahn, P. M. and Evans, D. A. (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59-64. https://doi.org/10.1097/00008571-199702000-00008
- Haselberger, M. B., Freedman, L. S. and Tolbert, S. (1997) Elevated serum phenytoin concentrations associated with coadministration of sertraline. J. Clin. Psychopharmacol. 17, 107-109. https://doi.org/10.1097/00004714-199704000-00008
- Horsmans, Y., Van den Berge, V., Bouckaert, A. and Desager, J. P. (1997) Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion. Pharmacol. Toxicol. 81, 276-279.
- Hung, C. C., Lin, C. J., Chen, C. C., Chang, C. J. and Liou, H. H. (2004) Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 26, 534-540. https://doi.org/10.1097/00007691-200410000-00012
- Mamiya, K., Ieiri, I., Shimamoto, J., Yukawa, E., Imai, J., Ninomiya, H., Yamada, H., Otsubo, K., Higuchi, S. and Tashiro, N. (1998) The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39, 1317-1323. https://doi.org/10.1111/j.1528-1157.1998.tb01330.x
- Mamiya, K., Kojima, K., Yukawa, E., Higuchi, S., Ieiri, I., Ninomiya, H. and Tashiro, N. (2001) Phenytoin intoxication induced by fluvoxamine. Ther. Drug Monit. 23 , 75-77. https://doi.org/10.1097/00007691-200102000-00014
- Nasu, K., Kubota, T. and Ishizaki, T. (1997) Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409. https://doi.org/10.1097/00008571-199710000-00011
- Odani, A., Hashimoto, Y., Otsuki, Y., Uwai, Y., Hattori, H., Furusho, K. and Inui, K. (1997) Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 62, 287-292. https://doi.org/10.1016/S0009-9236(97)90031-X
- Riva, R., Albani, F., Contin, M. and Baruzzi, A. (1996) Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin. Pharmacokinet. 31, 470-493. https://doi.org/10.2165/00003088-199631060-00005
- Schmider, J., Greenblatt, D. J., von Moltke, L. L., Karsov, D. and Shader, R. I. (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin phydroxylation. Br. J. Clin. Pharmacol. 44, 495-498. https://doi.org/10.1046/j.1365-2125.1997.00601.x
- Soga, Y., Nishimura, F., Ohtsuka, Y., Araki, H., Iwamoto, Y., Naruishi, H., Shiomi, N., Kobayashi, Y., Takashiba, S., Shimizu, K., Gomita, Y. and Oka, E. (2004) CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci. 74, 827-834. https://doi.org/10.1016/j.lfs.2003.07.018
- Spina, E., Pisani, F. and Perucca, E. (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin. Pharmacokinet. 31, 198-214. https://doi.org/10.2165/00003088-199631030-00004
- van der Weide, J., Steijns, L. S., van Weelden, M. J. and de Haan, K. (2001) The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11, 287-291. https://doi.org/10.1097/00008571-200106000-00002
- Watanabe, M., Iwahashi, K., Kugoh, T. and Suwaki, H. (1998) The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. Clin. Neuropharmacol. 21, 122-126.
- Wedlund, P. J. (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61, 174-183. https://doi.org/10.1159/000028398
- Yoon, Y. R., Shon, J. H., Kim, M. K., Lim, Y. C., Lee, H. R., Park, J. Y., Cha, I. J. and Shin, J. G. (2001) Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 51, 277-280. https://doi.org/10.1046/j.1365-2125.2001.00340.x
피인용 문헌
- Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation vol.29, pp.1, 2009, https://doi.org/10.2165/0044011-200929010-00004
- Clinical Association Between Pharmacogenomics and Adverse Drug Reactions vol.75, pp.6, 2015, https://doi.org/10.1007/s40265-015-0375-0
- Development of individualized medicine for epilepsy based on genetic information vol.1, pp.5, 2008, https://doi.org/10.1586/17512433.1.5.661
- From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics vol.33, pp.1, 2011, https://doi.org/10.1007/s11096-011-9485-2
- From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics vol.35, pp.3, 2013, https://doi.org/10.1007/s11096-010-9446-1
- Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs vol.10, pp.3, 2014, https://doi.org/10.1517/17425255.2014.872630
- The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention vol.127, pp.1, 2011, https://doi.org/10.1016/j.thromres.2010.10.021